A5045270299- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Retinoids in leukemia and cellular processes
- Acute Lymphoblastic Leukemia research
- Fatigue and fracture mechanics
- Hematopoietic Stem Cell Transplantation
- Hemoglobinopathies and Related Disorders
- Viral-associated cancers and disorders
- Vascular Tumors and Angiosarcomas
- Sarcoma Diagnosis and Treatment
- Plasma Diagnostics and Applications
- Titanium Alloys Microstructure and Properties
- Mechanical Engineering and Vibrations Research
- Kruppel-like factors research
- Gear and Bearing Dynamics Analysis
- Iron Metabolism and Disorders
- Erythropoietin and Anemia Treatment
- High-Velocity Impact and Material Behavior
- Immunodeficiency and Autoimmune Disorders
- Magnetic confinement fusion research
- Multiple Myeloma Research and Treatments
Nippon Steel (Japan)
2013-2024
Hiroshima University
2018
Yanmar (Japan)
2018
Nippon Steel (Germany)
2017
Kyoto University
2010-2016
Tokyo Medical University
2005-2014
Okayama University
2013
Kyoto Katsura Hospital
2013
Hokkaido University
2011
Osaka University
2005
Abstract Background: Even after the introduction of all‐ trans retinoic acid (ATRA), early hemorrhagic death remains a major cause remission induction failure for acute promyelocytic leukemia (APL). Methods: To investigate severe complications during therapy with respect to incidence, risk factors, and influence on outcome. Results were analyzed 279 patients enrolled in APL97 study conducted by Japan Adult Leukemia Study Group (JALSG). Results: Severe hemorrhage occurred 18 (6.5%). Although...
Summary The clinical significance of minimal residual disease (MRD) is uncertain in patients with Philadelphia chromosome‐positive acute lymphoblastic leukaemia (Ph+ ALL) treated imatinib‐combined chemotherapy. Here we report the results prospective MRD monitoring 100 adult patients. Three hundred and sixty‐seven follow‐up bone marrow samples, collected at predefined time points during a uniform treatment protocol, were analysed for BCR‐ABL1 transcripts by quantitative reverse transcription...
A number of CML patients who achieve a sustained complete molecular response (CMR) for at least 2 years during imatinib (IM) therapy can discontinue IM without relapse. With the long-term goal developing immunological criteria managing in patients, we compared immunophenotypic profiles three groups patients: those received and had CMR more than two consecutive (CMR group); did not have but maintained major (fluctuating with 6 months after discontinuation (STOP-IM group), together healthy...
Expression of CD56 has recently been introduced as one the adverse prognostic factors in acute promyelocytic leukemia (APL). However, clinical significance antigen APL not well elucidated. We assessed 239 patients prospectively treated with all-trans retinoic acid and chemotherapy according to Japan Adult Leukemia Study Group APL97 protocol. All were by The median follow-up period was 8.5 years. Positive expression found 23 (9.6%). significantly associated lower platelet count (P = 0.04),...
Studies focused on elderly acute promyelocytic leukemia (APL) are relatively limited. To evaluate prognostic impact in APL, we compared the long-term outcome of APL patients (60-70 years) with younger (15-59 treated all-trans retinoic acid combined anthracycline and cytarabine Japan Adult Leukemia Study Group (JALSG) APL97 study. Of 283 evaluable patients, 46 (16.3%) were who had more frequent lower platelet (P = 0.04), albumin 0.006) performance status 3 0.02), higher induction death rate...
Patients with haematological diseases occasionally exhibit liver dysfunction during treatment. This can have various causes such as therapy-related drugs and hepatitis B C infections, although the cause is unclear in some cases. It was recently reported that patients initially diagnosed drug-induced actually had E1. Several cases of transfusion-transmitted E infections also been reported1,2. In Japan, screening for does not appear to be performed at initial examination acute hepatitis. might...
The existence of isolated cytopenia in myelodysplastic syndrome (MDS) has been described, however, the exact clinico-hematologic features such MDS patients are still obscure. aim this study was to provide additive information on with thrombocytopenia comparison idiopathic thrombocytopenic purpura (ITP). We searched for 146 sequential and evaluated their clinical at time diagnosis. found 13/146 (8.9%) showing thrombocytopenia. These were male predominant (10:3) all diagnosed as refractory...
Myelodysplastic syndrome (MDS) with erythroid hypoplasia, a rare form of MDS, has not yet been clearly defined. We report four patients MDS hypoplasia who received immunosuppressive therapy. All were elderly, had severe transfusion‐dependent anaemia, morphological evidence myelodysplasia and low percentage (3·2–13·6%) precursors. Administration cyclosporin A (CsA) improved their anaemia; all achieved transfusion‐independence. An inverted CD4/8 ratio was seen in three also demonstrated T‐cell...
Expression of erythropoietin (EPO) receptor (EPO‐R) was analysed in leukaemia cells from 150 patients with acute myeloid (AML) or lymphoblastic (ALL). EPO‐R expressed 81 (60%) out 136 AML, and vitro treatment EPO led to proliferation 13 (16%) AML examined. expression response were observed all subtypes according the French–American–British (FAB) classification. All eight FAB‐M6 EPO‐R, one four showed an EPO. Although there no significant correlation ( r = 0.2522) between amount EPO, who...
A 66-year-old woman was admitted to our hospital for evaluation of edema the extremities. Laboratory findings suggested that she had nephrotic syndrome and chronic lymphocytic leukemia (CLL). Renal biopsy (with PAM staining) showed a spike formation in capillary wall. Immunofluorescent staining revealed deposition immunoglobulin G (IgG) third component complement glomerular basement membrane. Electron microscopy fibrillary deposits subepithelium. These indicated membranous glomerulonephritis...
Imatinib at a daily dose of 400 mg is the standard treatment for chronic myelogenous leukemia in phase. However, feasibility this small Japanese adults has not been clarified. We prospectively investigated toxicity and efficacy adult patients. Among 89 evaluable patients with median body weight 62.8 kg, imatinib therapy was held 40 subjects (45%), due to Grade 3-4 toxicities 30 (75%) 2 discretion attending physician 10 (25%). resumed gradually increased until 62 tolerated maintenance mg....